Patent Term Extension Application for BEYFORTUS® (nirsevimab-alip), Patent No. 11,661,449 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2024-E-0157

Patent Term Extension Application for BEYFORTUS® (nirsevimab-alip), Patent No. 11,661,449

Documents

Comments

Description

OPEN

Comment Period OpensJan 19, 2024

Comment Period ClosesAug 16, 2025

Type	Title	Posted	Comments	Status
Other	Letter to U.S. Patent and Trademark Office	Apr 20, 2026	--

CDER

Patent Term Extension Application

Fenwick & West LLP

AstraZeneca AB

BEYFORTUS (nirsevimab-alip)

Patent No. 11,661,449

OPEN